Next-Generation Therapeutic Strategies for Relapsed/Refractory Multiple Myeloma: Targeting BCMA

Experts discuss how they incorporate BCMA-targeted agents into the treatment of patients with MM and manage toxicities associated with these agents. This program features ClinicalThought commentaries downloadable slides and an on-demand webcast from a live webinar.

Share

Program Content

No activities added yet

Activities

Targeting BCMA in R/R MM
Current Strategies for Targeting BCMA in R/R Myeloma
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: September 09, 2021

Expires: September 08, 2022

R/R MM: Anti-BCMA Tx
FAQs on the Use of BCMA-Targeted Therapies for Relapsed or Refractory Multiple Myeloma
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: October 29, 2021

Expires: October 28, 2022

Activities

Anti-BCMA Tx in RR MM: Antibody–Drug Conjugates
BCMA-Targeted Antibody–Drug Conjugates in Multiple Myeloma
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: September 10, 2021

Expires: September 09, 2022

Anti-BCMA Tx in RR MM: CAR T-cell Therapy
BCMA-Targeted CAR T-Cell Therapy: Where Are We And Where Are We Going?
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: September 10, 2021

Expires: September 09, 2022

Anti-BCMA Tx in RR MM: Bispecific Antibodies
BCMA-Targeted Bispecific T-Cell Engagers and Bispecific Monoclonal Antibodies in R/R MM
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: September 10, 2021

Expires: September 09, 2022

EP: Anti-BCMA Tx in RR MM
ExpressPoints
Next-Generation Therapeutic Strategies for Relapsed/Refractory Multiple Myeloma: Targeting BCMA
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: October 05, 2021

Expires: October 04, 2022

Provided by

ProCE Banner

Supporters

Supported by educational grants from

GlaxoSmithKline

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC